A Phase II Study of Bi-weekly XELOX with Bevacizumab for patient with Metastatic Colorectal Cancer as first-line chemotherapy

Phase 2

• Conditions: advanced and/or recurrent colorectal cancer

• Registration Number: JPRN-UMIN000010259
• Lead Sponsor: Yamaguchi University Graduate School of Medicibe, Digestive surgery and surgical oncology

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2013-03-17
• Study Completion: 2022-03-31
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 45

Inclusion Criteria

Not provided

Exclusion Criteria

(1) Severe renal function disorder (2) History of serious drug hypersensitivity or a history of drug allergy (3) History of active double cancer within 5 years (4) Active infections (5) Distinctly abnormal ECG or cardiovascular disease (6) Cpmplication of thromboembolism,severe pulmonary disease(interstitial pneumonia, pulmonary fibrosis, mild Emphysema) "(7) complication of GI perforation or hemorrhage ,Paresis of intestine or intestinal obstruction " (8) Massive pleural effusion or ascites that required drainage (9) Brain metastasis (10) Complication of mental disorder,CNS disease, cerebrovascular disease. (11) Uncontrollable hypertension or diabetes mellitus (12) Uncontrollable diarrhea "(13) Patients with non-healing wounds,or surgery (thoracotomy, laparotomy) within 4 weeks " (14) Non-healing fracture (15) Bleeding diathesis or receiving anticoagulant drug(except Aspirin under 325mg/day) (16) Pregnant or lactating woman (17) Peripheral neuropathy (18) Other conditions not suitable for this study

Study & Design

• Study Type: Interventional
• Study Design: Not specified